According to the World Health Organization (WHO) a biomarker is “any substance, structure, or process that can be measured in the body or its products and influence or predict the incidence of outcome or disease” (WHO International Programme on Chemical Safety Biomarkers in Risk Assessment: Validity and Validation. 2001).
The platform provides to identification, development and validation of new diagnostic, prognostic and therapy response predictive biomarkers.
MAIN INFRASTRUCTURES AND METHODOLOGIES AVAILABLE
In the pre-analytical, analytical and post–analytical phase of the biomarker -development and -validation pipeline, the platform has experience in the design and development of new tests, standardization, analytical validation and clinical validation.
The platform provides technological expertise in proteomics, genomics and in immunoassays, expertise across a wide variety of diseases and expertise in clinical trials. It has available specialized facilities/structures that apply quality assurance system and it has access to biobank samples for retrospective studies.
The competence areas of platform are oncology, hereditary tumors, inflammation, rheumatology, neurodegenerative disorders, cardiovascular, infectious diseases, orthopedics, pharmacology, pharmacogenomics.
Biomarkers platform promotes training activities and interacts with other product platforms.
Assessment of clinical utility and impact
Clinical protocol planning and biomarker selection
Pre-analytical aspects and sample quality assessment
Chair: Dr. Egidio Iorio (ISS)
Co-Chair: Dr. Giovanni Blandino; Dr. Massimo Gion